We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

ASC Therapy for Patients With Severe Respiratory COVID-19 (ASC COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04341610
Recruitment Status : Withdrawn (Not approved by ethical committee)
First Posted : April 10, 2020
Last Update Posted : May 27, 2020
Information provided by (Responsible Party):
JKastrup, Rigshospitalet, Denmark

Brief Summary:

The emerging field of stem cell therapy holds promise of treating a variety of diseases. Especially the mesenchymal stromal cells from bone marrow or adipose tissue (ASCs) have proven their potential for regenerative therapy in patients with ischemic heart disease. Both of these cell types have putative immunomodulatory properties, as they have demonstrated their ability to evade recognition and actively suppress the immune system.

This knowledge is transferred into studies with COVID-19 patients having severe pulmonary dysfunction, to modify the virus induced immunological and inflammatory activity involved in the progression of disease often leading to prolonged ICU stay and in some occasion's death.

We will conduct a clinical trial in which patients with COVID-19 and severe pulmonary symptoms will be randomized to either placebo or treatment with allogeneic CSCC_ASCs from adipose tissue. The aim is to assess the impact of CSCC_ASCs on the activated immune system and clinical efficacy on pulmonary function.

The perspective is that this new information can be of pivotal importance and potentially be a paradigm shift for the clinical problems and severe outcome seen in some patients with severe COVID-19 and other severe diseases with Acute Respiratory Distress Syndrome.

Condition or disease Intervention/treatment Phase
Respiratory Tract Diseases Drug: Stem Cell Product Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-blind placebo-controlled
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind placebo-controlled
Primary Purpose: Treatment
Official Title: Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study
Estimated Study Start Date : April 20, 2020
Estimated Primary Completion Date : January 30, 2021
Estimated Study Completion Date : April 30, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: ASC
100 million allogeneic adipose-derived mesenchymal stromal cell
Drug: Stem Cell Product
100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline

Placebo Comparator: Placebo
Drug: Stem Cell Product
100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline

Primary Outcome Measures :
  1. Changes in clinical critical treatment index [ Time Frame: day 7 from randomization ]

Secondary Outcome Measures :
  1. Days of respirator treatment [ Time Frame: 3 months ]
  2. Improvement of clinical symptoms including duration of fever and respiratory need [ Time Frame: 3 months ]
  3. Mortality [ Time Frame: 3 months ]
  4. Marker of Immunological function -CD4+ and CD8+ T cell count [ Time Frame: 3 months ]
  5. C-reactive protein and leucocyte [ Time Frame: 3 months ]
  6. Cytokine profile [ Time Frame: 3 months ]
  7. Glomerular Filtration Rate [ Time Frame: 3 months ]
  8. Duration of hospitalization [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients between 18-80 years
  • Confirmed HCoV-19 infection
  • Temperature above 38.0o C
  • Pulmonary symptoms and signs, at least one of the following before clinical decision for intubation and respirator treatment:

    1. Respiratory distress, RR ≥ 30/min;
    2. Oxygen saturation ≤ 93% at rest state;
    3. Arterial partial pressure of oxygen (PaO2) / Fraction of inspiration O2 (FiO2) ≤ 300mmHg, 1mmHg=0.133kPa
  • Pneumonia that is judged by chest radiograph or computed tomography
  • In respirator and possible for treatment within the first 24 hours

Exclusion Criteria:

  • Patients that have need for additional immunosuppressive treatment
  • Patients with any past (within the past 3-5 years) or present malignancy (other than excised basal cell carcinoma).
  • Co-Infection with other infectious agent.
  • Females capable of becoming pregnant must have a negative pregnancy test prior to treatment. After inclusion, they must use contraceptives for 2 months following the given stem cell treatment. The pill, spiral, depot injection of progesterone, sub-dermal implantation, hormonal vaginal ring and transdermal patch regarded as safe contraceptives.
  • Patients who are participating in other clinical trials.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04341610

Layout table for location information
2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Layout table for additonal information
Responsible Party: JKastrup, Professor MD, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT04341610    
Other Study ID Numbers: EudraCT number: 2020-001330-36
First Posted: April 10, 2020    Key Record Dates
Last Update Posted: May 27, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Diseases